JNK Cancer Research Results

JNK, c-Jun N-terminal kinase (JNK): Click to Expand ⟱
Source:
Type:
JNK acts synergistically with NF-κB, JAK/STAT, and other signaling molecules to exert a survival function. Janus signaling promotes cancer cell survival.
JNK, or c-Jun N-terminal kinase, is a member of the mitogen-activated protein kinase (MAPK) family. It plays a crucial role in various cellular processes, including cell proliferation, differentiation, and apoptosis (programmed cell death). JNK is activated in response to various stress signals, such as UV radiation, oxidative stress, and inflammatory cytokines.
JNK activation can promote apoptosis in cancer cells, acting as a tumor suppressor. However, in other contexts, it can promote cell survival and proliferation, contributing to tumor progression.

JNK is often unregulated in cancers, leading to increased cancer cell proliferation, survival, and resistance to apoptosis. This activation is typically associated with poor prognosis and aggressive tumor behavior.
BC, Breast Cancer: Click to Expand ⟱
Breast Cancer
Scientific Papers found: Click to Expand⟱
1386- BBR,    Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
tumCV↓, ROS↑, JNK↑, MMP↓, Bcl-2↓, BAX↑, Cyt‑c↑, AIF↝,
13- CUR,    Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action
- Review, BC, NA
P53↑, DR5↑, JNK↑, NRF2↑, PPARγ↑, HER2/EBBR2↓, IR↓, ER(estro)↓, Fas↑, PDGF↓, TGF-β↓, FGF↓, EGFR↓, JAK↓, PAK↓, MAPK↓, ATPase↓, COX2↓, MMPs↓, IL1↓, IL2↓, IL5↓, IL6↓, IL8↓, IL12↓, IL18↓, NF-kB↓, NOTCH1↓, STAT1↓, STAT4↓, STAT5↓, STAT3↓,
6744- DSF,    Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, T47D
TumCD↑, ChemoSen↑, BAX↑, Apoptosis↑, CSCs↓, ROS↑, eff↝, JNK↑, p38↑, NF-kB↓,
1971- GamB,    Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis
- in-vitro, Nor, MCF10 - in-vitro, BC, MDA-MB-435 - in-vitro, BC, MDA-MB-468 - in-vivo, NA, NA
Paraptosis↑, ER Stress↑, MMP↓, eff↓, selectivity↑, p‑ERK↑, p‑JNK↑, eff↓,
7138- GI,    6-Shogaol exerts anti-proliferative and pro-apoptotic effects through the modulation of STAT3 and MAPKs signaling pathways
- vitro+vivo, BC, MDA-MB-231 - in-vitro, Pca, DU145 - in-vitro, Liver, HepG2 - in-vitro, Lung, A549
TumCP↓, TumMeta↓, p‑STAT3↓, JAK2↓, cSrc↓, JNK↑, p38↑, ERK↑, eff↓, ROS↑, cl‑PARP↑, TumCCA↑, Casp8↑, Casp9↑, Casp3↑, eff↑, Bcl-2↑, Bcl-xL↓, survivin↓, MMP9↓, COX2↓, IAP1↓, Dose?,
7247- Gink,    Ginkgetin inhibits growth of breast carcinoma via regulating MAPKs pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT474 - vitro+vivo, BC, MCF7
TumCP↓, Apoptosis↑, TumCG↓, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, Bcl-2↓, survivin↓, p‑ERK↑, cl‑JNK↑,
3305- SIL,    Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vivo, NA, NA
TumCP↓, tumCV↓, BAX↑, cl‑PARP↑, Casp9↑, p‑JNK↑, Bcl-2↓, p‑p38↓, p‑ERK↓, *toxicity∅, Dose↝, *hepatoP↑, Inflam↓, AntiCan↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

NRF2↑, 1,   ROS↑, 3,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↝, 1,   MMP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

IR↓, 1,   PPARγ↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 2,   BAX↑, 4,   Bcl-2↓, 3,   Bcl-2↑, 1,   Bcl-xL↓, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   Casp8↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 2,   cl‑Casp9↑, 1,   Cyt‑c↑, 1,   DR5↑, 1,   Fas↑, 1,   IAP1↓, 1,   JNK↑, 4,   p‑JNK↑, 2,   cl‑JNK↑, 1,   MAPK↓, 1,   p38↑, 2,   p‑p38↓, 1,   Paraptosis↑, 1,   survivin↓, 2,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

cSrc↓, 1,   HER2/EBBR2↓, 1,   PAK↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 1,   cl‑PARP↑, 3,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   ERK↑, 1,   p‑ERK↓, 1,   p‑ERK↑, 2,   FGF↓, 1,   NOTCH1↓, 1,   STAT1↓, 1,   STAT3↓, 1,   p‑STAT3↓, 1,   STAT4↓, 1,   STAT5↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

ATPase↓, 1,   MMP9↓, 1,   MMPs↓, 1,   PDGF↓, 1,   TGF-β↓, 1,   TumCP↓, 3,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 2,   IL1↓, 1,   IL12↓, 1,   IL18↓, 1,   IL2↓, 1,   IL5↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 1,   JAK↓, 1,   JAK2↓, 1,   NF-kB↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ER(estro)↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose?, 1,   Dose↝, 1,   eff↓, 3,   eff↑, 1,   eff↝, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,  
Total Targets: 82

Pathway results for Effect on Normal Cells:


Functional Outcomes(tgid=23) ⓘ

hepatoP↑, 1,   toxicity∅, 1,  
Total Targets: 2

Scientific Paper Hit Count for: JNK, c-Jun N-terminal kinase (JNK)
1 Berberine
1 Curcumin
1 Disulfiram
1 Gambogic Acid
1 Ginger/6-Shogaol/Gingerol
1 Ginkgetin
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:4  Cells:%  prod#:%  Target#:168  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page